AAPL343.20-0.26 (-0.08%) ▼|ABBV283.13-2.29 (-0.80%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.90+7.22 (+3.14%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.05-2.22 (-1.20%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.37+2.78 (+0.88%) ▲|BA191.51+1.30 (+0.68%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.83-9.56 (-0.84%) ▼|BMY58.84-0.91 (-1.52%) ▼|BNY142.41-0.89 (-0.62%) ▼|BRK-B532.47+0.45 (+0.08%) ▲|C121.72-2.54 (-2.04%) ▼|CAT725.77-4.99 (-0.68%) ▼|CL93.40-0.71 (-0.75%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.86-1.88 (-0.93%) ▼|COP145.21-1.30 (-0.89%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.46+1.76 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.34%) ▲|CVX224.48-0.51 (-0.23%) ▼|DE627.30-14.56 (-2.27%) ▼|DHR224.39-4.65 (-2.03%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK119.26-2.21 (-1.82%) ▼|EMR160.52-0.95 (-0.59%) ▼|FDX293.81+0.26 (+0.09%) ▲|GD341.40-2.83 (-0.82%) ▼|GE311.34-2.49 (-0.79%) ▼|GEV908.35-12.85 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.72-1.24 (-1.48%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.79-5.47 (-0.62%) ▼|HD309.99+0.36 (+0.12%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.36+4.22 (+1.82%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.96-1.60 (-0.63%) ▼|JPM333.63-6.09 (-1.79%) ▼|KO93.44-0.47 (-0.50%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.40-16.63 (-1.32%) ▼|LMT548.45-3.64 (-0.66%) ▼|LOW195.90-1.48 (-0.75%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.27-1.15 (-0.19%) ▼|MCD242.63-0.34 (-0.14%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.74-2.01 (-2.12%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.10-2.65 (-1.61%) ▼|MO74.07-1.05 (-1.39%) ▼|MRK143.67-2.28 (-1.56%) ▼|MS178.49-2.08 (-1.15%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.18-1.62 (-2.03%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.22+0.09 (+0.24%) ▲|NOW145.35+3.38 (+2.38%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.63+1.40 (+1.09%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.43-0.15 (-0.51%) ▼|PG157.71-1.64 (-1.03%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM200.98-4.22 (-2.06%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.28-10.72 (-1.55%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|AAPL343.20-0.26 (-0.08%) ▼|ABBV283.13-2.29 (-0.80%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.90+7.22 (+3.14%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.05-2.22 (-1.20%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.37+2.78 (+0.88%) ▲|BA191.51+1.30 (+0.68%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.83-9.56 (-0.84%) ▼|BMY58.84-0.91 (-1.52%) ▼|BNY142.41-0.89 (-0.62%) ▼|BRK-B532.47+0.45 (+0.08%) ▲|C121.72-2.54 (-2.04%) ▼|CAT725.77-4.99 (-0.68%) ▼|CL93.40-0.71 (-0.75%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.86-1.88 (-0.93%) ▼|COP145.21-1.30 (-0.89%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.46+1.76 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.34%) ▲|CVX224.48-0.51 (-0.23%) ▼|DE627.30-14.56 (-2.27%) ▼|DHR224.39-4.65 (-2.03%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK119.26-2.21 (-1.82%) ▼|EMR160.52-0.95 (-0.59%) ▼|FDX293.81+0.26 (+0.09%) ▲|GD341.40-2.83 (-0.82%) ▼|GE311.34-2.49 (-0.79%) ▼|GEV908.35-12.85 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.72-1.24 (-1.48%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.79-5.47 (-0.62%) ▼|HD309.99+0.36 (+0.12%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.36+4.22 (+1.82%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.96-1.60 (-0.63%) ▼|JPM333.63-6.09 (-1.79%) ▼|KO93.44-0.47 (-0.50%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.40-16.63 (-1.32%) ▼|LMT548.45-3.64 (-0.66%) ▼|LOW195.90-1.48 (-0.75%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.27-1.15 (-0.19%) ▼|MCD242.63-0.34 (-0.14%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.74-2.01 (-2.12%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.10-2.65 (-1.61%) ▼|MO74.07-1.05 (-1.39%) ▼|MRK143.67-2.28 (-1.56%) ▼|MS178.49-2.08 (-1.15%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.18-1.62 (-2.03%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.22+0.09 (+0.24%) ▲|NOW145.35+3.38 (+2.38%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.63+1.40 (+1.09%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.43-0.15 (-0.51%) ▼|PG157.71-1.64 (-1.03%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM200.98-4.22 (-2.06%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.28-10.72 (-1.55%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|
18 C
New York
Monday, October 19, 2026

Tag: sites

newssourceFORcompanycontentinformation1releasesmarket

Driving emissions transparency: INEOS Styrolution rolls out product carbon footprint calculations across global portfolio

PCF platform automates product carbon footprint calculations and enables customer monitoring of scope 3.1 emissions for INEOS Styrolution productsMethodology certified by TÜV Rheinland and...

LNG Station Market worth $1.56 billion by 2030 | MarketsandMarkets™

DELRAY BEACH, Fla., June 16, 2025 /PRNewswire/ -- The global LNG Station Market is anticipated to grow from estimated USD 1.02 billion in 2025 to...

Powerful, Compact, Smart: Jackery Launches the Lightest 3kWh Explorer 3000 v2

LONDON, June 16, 2025 /PRNewswire/ -- Jackery, a leading provider of portable power solutions, unveils its latest flagship model: the Explorer 3000 v2 — the brand's...

Global Times: Practitioners’ Insights: Urban-rural bus Route 101 – a vivid practice of ‘following a good blueprint through to the end’

BEIJING, June 15, 2025 /PRNewswire/ -- In the early morning, the lights of the Daxin Road bus hub in downtown Jiaxing cut through the mist....

Relax, Recharge, Repeat: Agoda Unveils Asia’s Top Wellness Escapes

SINGAPORE, June 16, 2025 /PRNewswire/ -- Digital travel platform Agoda has curated a list of Asia's most rejuvenating wellness destinations, perfect for travelers seeking holistic,...

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy...

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Zilliz Transforms Video Surveillance Industry with AI-Powered Vector Database Solutions

Leading surveillance providers leverage Zilliz Cloud to overcome data overload challenges, enabling real-time threat detection and sub-second video search across enterprise installations. REDWOOD SHORES, Calif.,...

Investigational combination of first-in-class bispecific antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary...

Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA1 

Nuclear Air Filtration for HVAC Managers: Why the Nuclear Comeback Demands Next-Gen Filtration Standards

The Big Reveal: What HVAC Managers Must Know About High-Performance Filtration. Camfil Nuclear air filters are used for containment control during dismantling or maintenance work at a nuclear sites. 
The Big Reveal:  What HVAC Managers Must Know About High-Performance Filtration. Camfil Nuclear air filters are used for containment control during dismantling or maintenance work at a nuclear sites.

K-Bro Declares June 2025 Dividend

(TSX: KBL) EDMONTON, AB, June 13, 2025 /CNW/ - K-Bro Linen Inc. (the "Corporation") announced today a dividend of 10.00 cents CDN per common share...

$1 Deposit Casinos Canada: RoboCat Casino Launches 1 Dollar Deposits

RoboCat now accepts deposits from just $1 and offers exclusive bonuses and rewards on small deposits, making online casino gaming more accessible for everyone 
RoboCat now accepts deposits from just $1 and offers exclusive bonuses and rewards on small deposits, making online casino gaming more accessible for everyone

Trusted Crypto Casinos Are Taking Over Online Gambling in 2025: Exclusive Report By Radcred

Radcred’s exclusive 2025 study reveals the safest, fastest-paying crypto casinos reshaping online gambling. See trends, data, and tips. 
Radcred’s exclusive 2025 study reveals the safest, fastest-paying crypto casinos reshaping online gambling. See trends, data, and tips.

Beyond IT: Digital Transformation Market Size Set to Hit US$4,617.78 billion by 2030 at 27.6% CAGR, Says The Research Insights

CHICAGO, June 13, 2025 /PRNewswire/ -- The Global Digital Transformation Market size is projected to be valued at USD 1,070.43 billion in 2024 and reach USD 4,617.78...

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSites

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers